First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye
About This Grant
Dry Eye Disease (DED) affects 20% of the global adult population, with higher rates in developed countries like the USA. It significantly impacts quality of life, productivity, increases healthcare costs, and can lead to vision loss if untreated. Current therapies are incapable of addressing chronic DED as they cannot be used long-term due to their toxicity. Our innovative First-In-Class mitochondrial technology targets the root cause of DED by addressing oxidative stress and mitochondrial dysfunction, which induces Meibomian Gland Dysfunction (MGD), a predominant cause of DED. Due to its unique mechanism of action, our drug candidate is safe for long-term use and offers a broader therapeutic window. This noninvasive treatment promises to revolutionize eye care and provide a sustainable solution to this widespread health challenge. Our proprietary small molecule lead candidate exhibits dose dependent free radical scavenging potential with calculated IC50 of 2.1µM and was found to protect various ocular cell lines against oxidative stress. It was found to be highly efficacious in reducing Benzalkonium chloride induced dry eye, tissue damage and vascularization in mice model of dry eye. An ophthalmic safety study suggests that an acute TID dose of our candidate as eye drops up to 30 µg/eye (total dose of 90 µg/eye/day) was well tolerated in New Zealand White rabbits. We have secured our invention by the filing of patent applications in the USA (US2021163159081), China (CN2280008594), India (IN202317001652), Canada (CA3205099A1), EU (EP22767950.3), Brazil (BR 1120230181097), Australia (AUS 2022234307) and Japan (JP2023-555226) for compounds, compositions, and their method of use. The novelty of our invention is confirmed by a written opinion from USPTO and an enhanced freedom to operate searches by qualified patent attorneys. DED is a multifactorial indication; therefore, in proposed SBIR phase I, our proposed studies entail In vivo characterization of lead candidates in desiccating stress/scopolamine (DSS) model of DED in mice working through varied etiologies. We also propose to evaluate the toxicity of our lead in repeated dose 7-day rabbit model of toxicity with PK parameters and local biodistribution in eye tissues of rabbits. Successful completion of proposed studies will be followed by submission of a phase-II SBIR to conduct a set of IND-enabling pre-clinical studies, manufacturing process scaleup and development, and analytical method validation, GLP toxicity studies with recovery group. Setup of in-house eCTD software interface and electronic submission gateway (ESG) with FDA and relevant certifications of personnel and workstation infrastructure will also be included in the SBIR phase-II application. We have assembled an experienced team consisting of chemists, drug discovery and bench to bedside drug product development experts, pharmacologists, ocular pharmacokinetics, toxicologists, ophthalmologists, regulatory experts, and industry partners. We are confident of successfully completing the proposed work.
Grant Summary
First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye is a NEI - National Eye Institute grant providing up to $349K for university, nonprofit, healthcare org. Applications are due 2026-09-29 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $349K
2026-09-29
- 1Confirm your organization is eligible for First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye from NEI - National Eye Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NEI - National Eye Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NEI - National Eye Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye: Frequently Asked Questions
Who is eligible for the First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye?
First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye is offered by NEI - National Eye Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye provide?
First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye provides up to $349K per award from NEI - National Eye Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye deadline?
Applications for First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye are due 2026-09-29 (open). Because deadlines can change, verify the date with the funder, NEI - National Eye Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye?
To apply for First in Class Mitochondrially targeted antioxidants with transcriptional modulator capabilities and their implication in the diseases of the eye, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NEI - National Eye Institute.